10 Questions
What does clinical pharmacokinetics study?
The absorption, distribution, metabolism, and excretion of drugs
Why is it important to establish the relationship between concentration and effect in pharmacokinetics?
To ensure the patient receives the correct drug dose
How is levodopa associated with Parkinson's disease management?
It can lead to motor complications like on-off problems and dyskinesias
Besides motor features, what is now known to contribute significantly to the quality of life of Parkinson's disease patients?
Non-motor symptoms that may appear even before disease onset
What is a potential treatment option for motor complications associated with levodopa use?
Deep brain stimulation
What population percentage does Parkinson's Disease (PD) affect in individuals over 65 years of age?
1%
When did environmental factors become relevant in understanding Parkinson's Disease?
1980s
Which of the following is NOT associated with an increased risk of developing Parkinson's Disease?
Tobacco smoking
What is the gender predominance in Parkinson's Disease demographically?
3:2 (male:female)
Which accidental toxin had similarities in structure to MPTP, leading to exploration of chemical roles in Parkinson's Disease?
Paraquat
Study Notes
Clinical Pharmacokinetics
- Clinical pharmacokinetics is the study of the time course of drug absorption, distribution, metabolism, and excretion, and their corresponding pharmacological response.
- It models what happens to a drug after administration to a patient.
- Establishing the relationship between concentration and effect is crucial for pharmacokinetics to be beneficial to the patient.
Parkinson's Disease (PD)
- PD affects 1% of the population over 65 years old, increasing to 2% over 80 years old.
- One in 20 patients is diagnosed before their 40th year.
- PD affects around 127,000 people in the UK, with over 6 million sufferers worldwide.
- Demographically, the disease has a small male/female predominance (around 3:2).
- Prevalence is higher in European and North and South American populations compared to Arabic, African, and Asian countries.
Risk Factors and Causes
- Age is the biggest risk factor for PD, with major implications for public health as the global population ages.
- Both genetic and environmental factors contribute to the risk of developing PD.
- Environmental factors can precipitate the onset of PD in a genetically susceptible individual.
- Pesticide exposure, rural living, agricultural occupation, and well water drinking are associated with an increased risk of developing PD.
- Tobacco smoking, coffee drinking, non-steroidal anti-inflammatory drug use, calcium channel blocker use, and alcohol consumption are linked to a reduced risk of the disease.
Motor Features and Treatment
- Levodopa is used to manage some motor features of PD, but it is associated with motor complications after some years, such as on–off problems and dyskinesias.
- Other therapeutics, including deep brain stimulation, can be used to treat these complications.
- Non-motor symptoms, present from disease onset, contribute significantly to the quality of life of patients with PD, presenting a complex therapeutic challenge.
Parkinsonism
- Parkinsonism describes the main motor features of PD, but can also be a feature of other neurodegenerative conditions, such as multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration.
- Parkinsonism can also be a side effect of various medications.
Test your knowledge on the study of the time course of drug absorption, distribution, metabolism, and excretion, as well as their pharmacological response. Explore how pharmacokinetics can be applied in various clinical scenarios.
Make Your Own Quizzes and Flashcards
Convert your notes into interactive study material.
Get started for free
